Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. - Wikidata - wikimedia - TriplyDB

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.

http://www.wikidata.org/entity/Q37760957

about

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Phosphine-Catalyzed [3+2] and [4+3]Annulation Reactions of C,N-Cyclic Azomethine Imines with Allenoates Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012.Finding chemo: the search for marine-based pharmaceutical drugs active against cancer.Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.Trabectedin has promising antineoplastic activity in high-grade meningioma.

P2860

Q33921802-F7D96B12-4D8B-45DB-9264-75FFFE6971BC Q34706915-9D8DB368-A5EC-4F47-AB6B-CCB7F48F5AB2 Q35015321-8E105730-0632-4E3A-8016-023B9FD83049 Q38127449-8FCC7ADA-ADD0-4BAD-ABC7-BC6127658008 Q38720938-0D5CBB6F-A51E-4DEC-9E99-465DF8F2C913 Q42195995-E3257925-EB7B-44FC-BA0C-72B356C5D32B Q48627774-E3ABDF17-CB66-4EAC-9534-354E51709628

P2860

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.

http://www.wikidata.org/entity/Q37760957

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Wide-spectrum characterization ...... ivity and future perspectives.

@en

Wide-spectrum characterization ...... ivity and future perspectives.

@nl

type

label

Wide-spectrum characterization ...... ivity and future perspectives.

@en

Wide-spectrum characterization ...... ivity and future perspectives.

@nl

prefLabel

Wide-spectrum characterization ...... ivity and future perspectives.

@en

Wide-spectrum characterization ...... ivity and future perspectives.

@nl

P1433

Q37760957-DF2B23FC-38F2-455A-A1E0-5E8769C75E10

P1476

Q37760957-5880587A-7857-404E-9B17-DBFA49642271

P2093

Q37760957-0244EFAE-0F90-41A0-AFBE-65C1646A5B93

Q37760957-1472A061-DFEE-4EC6-8BD1-68FFEB3490AD

Q37760957-7B41E401-6B53-4AA9-8780-DF5DC567FF44

Q37760957-C4DB267F-732F-4191-B64D-BA5C896E18BF

P2860

Q37760957-0260B4F8-1A34-436E-982B-62FC08E3590E

Q37760957-04B48656-BCEF-4140-85EC-4D56A83E5FF7

Q37760957-069A308D-3917-4F70-96AC-CF581D7788D4

Q37760957-06FEA046-81E5-4DC3-B018-AFA43B253AAB

Q37760957-075FEFDD-2729-443C-B73A-B8DA920A386B

Q37760957-0880342D-013A-4FEE-8878-9B9C4411726E

Q37760957-0BA00002-281B-4FE8-A605-B8527B91200F

Q37760957-0C90B44C-69BC-4D76-8FB1-A54434ED9B19

Q37760957-13587E93-0535-421A-B99C-3B7DEA72AC12

Q37760957-14B2EF86-28F1-420D-B4DA-FEBA423A009E

P304

Q37760957-8A00EF79-0C2F-4DB4-ABF1-11BBA2E947E2

P31

Q37760957-1F4C789F-80D1-4567-AF0D-CAAC3A773C09

P356

Q37760957-AE7609B1-9435-4FDA-B9C1-72C69F21E7F4

P433

Q37760957-F39ED7DA-2CD7-4F1D-B9D4-88EA53E4E842

P478

Q37760957-BDB1A8A9-0B57-4468-B17A-09DCA3FB86A9

P50

Q37760957-33E6645C-8846-4D9C-9655-0725C94DFAC9

Q37760957-BDF59770-0309-493C-A3C1-428147F2FB8B

P577

Q37760957-EDEEF7C1-4192-4533-A0C5-436CFC96B9D0

P5875

Q37760957-02A1724F-625F-4B2F-951A-60F65B930CA6

P698

Q37760957-EFC46907-9D67-432C-8CE7-79947AC0C0BD

P356

P1433

Pharmacogenomics

P1476

Wide-spectrum characterization ...... ivity and future perspectives.

@en

P2093

Anna Maria Frezza

http://www.w3.org/2001/XMLSchema#string

Bruno Vincenzi

http://www.w3.org/2001/XMLSchema#string

Gaia Schiavon

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tonini

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumor compounds from tunicates

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

P304

865-878

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.10.69

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Andrea Napolitano

Daniele Santini

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44631992

http://www.w3.org/2001/XMLSchema#string

P698

20504257

http://www.w3.org/2001/XMLSchema#string